The faecal tumour M2-PK screening test for invasive & pre-invasive colorectal cancer: Estimated specificity & results as a function of age for a study population of 4854 volunteers;Badania przesiewowe na obecność kinazy pirogronianowej M2 w stolcu u chorych z inwazyjnym i przedinwazyjnym rakiem jelita grubego: Szacunkowa swoistość metody oraz wyniki uzyskane w grupie 4854 ochotników, przedstawione w funkcji wieku

Nowotwory

Volumn 59, Issue 2, 2009, Pages 75-81

  Tonus, Carolin ^a   Neupert, Gero ^a   Witzel, Kai ^a  

^a Herz Jesu Krankenhaus Fulda   (Germany)

Author keywords

Adenoma; Bowel cancer; Cancer screening; Colorectal cancer; Polyps; Pyruvate kinase type M2; Tumour M2 Pyruvate kinase

Indexed keywords

PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; COLORECTAL CANCER; COST; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PREVALENCE; SCREENING TEST;

EID: 66949127947     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J i wsp. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74-108
2. Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 2007; 57: 90-104.
3. Schmiegel W, Pox C, Adler G i wsp. Deutschen Gesellschaft für Verdauungs - und Stoffwechselkrankheiten; Deutschen Krebshilfe; Deutschen Krebsgesellschaft; Deutschen Gesellschaft für Hämatologie und Onkologie; Deutschen Gesellschaft fur Innere Medizin; Deutschen Gesellschaft für Koloproktologie; Deutschen Gesellschaft für Pathologie; Deutschen Gesellschaft für Radioonkologie; Deutschen Gesellschaft für Viszeralchirurgie; Deutschen Röntgengesellschaft; Deutschen vereinten Gesellschaft für klinische Chemie und Laboratoriumsmedizin e.V. [S3-guideline conference "Colorectal Cancer" 2004] Dtsch Med Wochenschr 2005; 130 Suppl 1: S5-53. Review. German.
4. Rhodes JM. Colorectal cancer screening in the UK: Joint Position Statement by the British Society of Gastroenterology, The Royal College of Physicians & The Association of Coloproctology of Great Britain and Ireland. Gut 2000; 46: 746-748 (Pubitemid 30329062)
5. Australian Cancer Network Colorectal Cancer Guidelines Revision Committee. Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer. Sydney: The Cancer Council Australia & Australian Cancer Network, 2005.
6. Waye JD, Kahn O, Auerbach ME. Complications of colonoscopy and flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 1996; 6: 343-347 (Pubitemid 26116046)
7. Darmkrebs - wenig Resonanz auf Angebot zur Früherkennung. Ärztezeitung. 27.10.2004.
8. Macrae FA, St.John DJB. Relationship between patterns of bleeding and hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982; 82: 891-898
9. Lieberman DA, Harford WV, Ahnen DJ i wsp. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345: 555-560 (Pubitemid 32772096)
10. Koss K, Maxton D, Jankowski JA. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis 2008; 10: 244-248
11. Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ann Intern Med 1997; 126: 811-822
12. Hardcastle JD, Chamberlain JO, Robinson MHE i wsp. Randomised controlled trial of faecal occult blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477 (Pubitemid 26400242)
13. Mandel J, Church TR, Ederer F, Bond JH. Effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434-437
14. Ewald N, Toepler M, Akinci A i wsp. Pyruvatkinase M2 (Tumor M2-PK) im Stuhl als Screeningparameter for kolorektale Neoplasien. Eine Übersicht über bisher publizierte Daten. Z Gastroenterol 2005; 43: 1313-1317 (Pubitemid 43041363)
15. Hardt PD, Toepler M, Ngoumou B i wsp. Measurement of fecal pyruvate kinase type M2 (Tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003; 23(2A): 851-853 (Pubitemid 36750884)
16. Hardt PD, Mazurek S, Toepler M i wsp. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91: 980-984 (Pubitemid 39273794)
17. McLoughlin R, Shiel E, Sebastian S i wsp. Tumor M2-PK, a novel screening tool for colorectal cancer. In: Poster Abstracts & Trade Exhibition Book: NCRI Cancer Conference; 2005 Oct 2-5; Birmingham, United Kingdom. London: Callisto, 2005:202.
18. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol. 2006, 12: 7007-7011 (Pubitemid 44834892)
19. Ewald N, Schaller M, Bayer M i wsp. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer. Anticancer Res 2007; 27:1949-1952 (Pubitemid 46954705)
20. Kumar Y, Tapuria N, Kirmani N i wsp. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 2007; 19: 265-276, review. (Pubitemid 46263285)
21. Hathurusinghe HR, Goonetilleke KS, Siriwardena AK. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann Surg Oncol 2007; 14:2714-2720, review. (Pubitemid 47460645)
22. Eigenbrodt E, Reinacher M, Scheefers-Borchel U i wsp. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncogenesis 1992; 3:91-115.
23. Christofk HR, Van der Heiden MG, Wu N i wsp. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008; 452: 181-186
24. Reinacher M, Eigenbrodt E. Immunohistological demonstration of the same type of pyruvate kinase isoenzyme (M2-PK) in tumors of chicken and rat. Virchows Arch B Cell Pathol Incl Mol Pathol 1981; 37: 79-88. (Pubitemid 11070025)
25. Board M, Humm S, Newsholme EA. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J 1990; 265: 503-509 (Pubitemid 20041995)
26. Hacker HJ, Steinberg P, Bannasch P. Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis 1998; 19: 99-107. (Pubitemid 28376831)
27. Christofk HR, Van der Heiden MG i wsp. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452:230-233
28. Discher DJ, Bishopric NH, Wu X i wsp. Hypoxia regulates β-enolase and pyruvate kinase promoters by modulating Sp1/Sp3 binding to conserved GC element. J Biol Chem 1998; 273:26087-26093 (Pubitemid 28475843)
29. 2 homeostasis. Curr Opin Genet Dev 1998; 8:588-594 (Pubitemid 28477364)
30. Mazurek S, Zwerschke W, Jansen-Durr P i wsp. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 2001; 20: 6891-6898 (Pubitemid 33052178)
31. Nishikawa T, Maemura K, Hirata I i wsp. A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/restriction fragment length polymorphism analysis. Clin Chim Acta 2002; 318:107-112 (Pubitemid 34195593)
32. Mazurek S, Boschek B, Hugo F i wsp. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15: 300-308 (Pubitemid 41058775)
33. Oremek GM, Teigelkamp S, Kramer W i wsp. The Pyruvate Kinase Isoenzyme Tumor M2 (Tu M2-PK) as a Tumor Marker for Renal Carcinoma Anticancer Res 1999; 19: 2599-2602
34. Wechsel HW, Petri E, Bichler KH i wsp. Marker for renal cell carcinoma (RCC); the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 1999;19:2583-2590 (Pubitemid 29392417)
35. Lueftner D, Mesterharm J, Akrivakis C i wsp. Tumor Type M2 Pyruvate Kinase expression in advanced breast cancer. Anticancer Res 2000; 20: 5077-5082 (Pubitemid 32319084)
36. Schneider J, Morr H, Velcovsky HG i wsp. Quantitative detection of Tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev 2000; 24: 531-535 (Pubitemid 32099839)
37. Kaura B, Bagga R, Patel FD. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res 2004; 30: 193-196 (Pubitemid 38855821)
38. Ventrucci M, Cipolla A, Racchini C i wsp. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 2004; 49: 1149-1155 (Pubitemid 39178081)
39. Zhang B, Chen JY, Chen DD i wsp. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol 2004; 10: 1643-1646 (Pubitemid 38786947)
40. Goonetilleke KS, Mason JM, Siriwardana P i wsp. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Pancreas 2007, 34:318-324 (Pubitemid 46588257)
41. Naumann M, Schaum B, Oremek GM i wsp. Faecal pyruvate kinase type M2 - a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochenschr 2004; 129: 1806-1807 (Pubitemid 39221985)
42. Vogel T, Driemel C, Hauser A i wsp. Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr 2005; 130: 872-877 (Pubitemid 40545296)
43. Shastri YM, Naumann M, Oremek GM i wsp. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer 2006; 119: 2651-2656 (Pubitemid 44691321)
44. Haug U, Rothenbacher D, Wente MN i wsp. Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br J Cancer 2007; 96: 1329-1334 (Pubitemid 46685781)
45. Segnan N, Senore C, Andreoni B i wsp. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy" - SCORE. J Natl Cancer Inst 2002; 94: 1743-1772
46. Liu HH, Wu MC, Peng Y, Wu MS. Prevalence of advanced colonic polyps in asymptomatic Chinese. World J Gastroenterol 2005; 11: 4731-4734 (Pubitemid 41179532)